+11%

est. 2Y upside i

HealthcareSeries D+

Maven is a new platform for cohort-based courses started by the founders of Udemy, altMBA and Socratic. We partner with the world’s best instructors to offer live, online, community-driven courses to transform your career.

Rank

#1796

Sector

Digital Health, Women's and Family Health, HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

Maven offers a moderate risk/reward with 11% expected upside over 2 years, driven by an impending IPO.

Last updated: July 19, 2026

Bull (25%)+73%

Maven executes an IPO with strong demand, trading at 8x forward ARR of $367M, valuing the company at $2.94B, a 73% upside from entry.

Base (55%)+8%

Revenue grows steadily but valuation multiple compresses to 5x forward ARR, yielding $1.84B valuation, a 7.9% gain.

Bear (20%)-57%

Growth slows, multiple contracts to 2x, valuation drops to $734M, a 57% loss, but still above liquidation preference.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

25%

Preferred stock totals $425M, representing 25% of the current valuation, which could absorb a significant portion of returns in a downside scenario.

Dilution Risk

moderate

No significant raise expected within 24 months, but ongoing option grants may dilute existing shareholders.

Secondary Liquidity

none

No active secondary market; liquidity will come from IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Maven's data — designed to show you've done your homework.

  • 1

    “How does Maven differentiate from Progyny's more narrowly focused fertility benefits?”

  • 2

    “What is the unit economics of your B2B2C model, and how does it scale with enterprise contracts?”

  • 3

    “Given the IPO readiness, what is your timeline for going public and how will that affect equity liquidity?”

Community

Valuation Sentiment

Our model estimates +11% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.